-60%

est. 2Y upside i

Series B

Cheese and dairy products from plant-derived dairy proteins

Rank

#1362

Sector

Food Tech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Alpine Bio (formerly Nobell Foods) presents a strong upside opportunity driven by its patented molecular farming technology for producing dairy-identical proteins and its expanded platform beyond cheese.

Last updated: March 10, 2026

Bull (25%)+300%

Alpine Bio successfully launches its Nobell Foods mozzarella in 2025, achieving rapid market acceptance due to superior taste and texture. The broader Alpine Bio platform secures major B2B partnerships for its casein and high-value lactoferrin, proving its patented molecular farming technology is highly cost-effective and scalable, leading to a $2B+ valuation.

Base (40%)+50%

Nobell Foods cheese launches in 2025 and gains moderate traction, but faces stiff competition and slower-than-expected scaling. Alpine Bio secures initial B2B partnerships for its protein platform, but regulatory approvals and full commercialization take longer, resulting in a $750M valuation.

Bear (35%)-70%

Significant regulatory delays for genetically engineered ingredients, limited consumer acceptance, or strong competitive pressure from well-funded precision fermentation companies lead to slower adoption and a down round, resulting in a valuation of $150M, significantly impacting common stock value.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

21%

Investors hold $103M in liquidation preferences ahead of common stock, meaning in an exit at or below $500M, common stock holders would see significantly reduced returns.

Dilution Risk

high

As a pre-revenue, capital-intensive company with a broad platform, Alpine Bio will likely require additional significant funding rounds, leading to further dilution of existing equity.

Secondary Liquidity

none

Given the company's stage (Series B) and pre-revenue status for its core product, active secondary markets or tender offers are unlikely at this time.

Questions to Ask at the Interview

Strategic questions based on Nobell Foods's data — designed to show you've done your homework.

  • 1

    “Given the rebranding to Alpine Bio and the expanded focus beyond cheese, how is the company prioritizing the development and commercialization of its 15+ protein pipeline, particularly in light of the B2B model shift?”

  • 2

    “What is Alpine Bio's detailed strategy for navigating the high regulatory barriers for genetically engineered ingredients, and what are the key milestones and timelines for achieving GRAS status and other necessary approvals for both casein and lactoferrin?”

  • 3

    “How does Alpine Bio plan to differentiate its molecular farming approach from precision fermentation competitors like Perfect Day and New Culture, especially regarding cost-competitiveness, scalability, and consumer acceptance of GMO-derived products?”

  • 4

    “With a Series B valuation of $500M and $103M in total funding, what are the company's expectations for future funding rounds, and how is the leadership team thinking about managing potential dilution and creating liquidity events for employees within a 2-4 year horizon?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.